BTBP(SH:600161)2018-10-12 16:00Financial Performance - Total operating revenue for the first three quarters of 2018 reached CNY 2,056.59 million, an increase of 27.68% compared to the previous year's adjusted figure of CNY 1,610.79 million[3] - Net profit attributable to shareholders of the listed company was CNY 396.60 million, a decrease of 60.39% from the previous year's adjusted figure of CNY 1,001.35 million[3] - Basic earnings per share decreased to CNY 0.46, down 60.39% from the previous year's adjusted figure of CNY 1.15[3] - The weighted average return on equity dropped to 10.42%, a decrease of 19.77 percentage points from the previous year's adjusted figure of 30.19%[3] - The company recorded a substantial decrease in operating profit and total profit due to the previous year's one-time investment gains of CNY 758 million from the sale of stakes in two subsidiaries[6] Blood Products Business - The net profit from blood products business was CNY 568.20 million, representing a 47.93% increase from the previous year's adjusted figure of CNY 384.10 million[6] - The company expects significant growth in blood products business performance due to increased marketing efforts and refined management practices[5] - The company has integrated three blood product companies into its consolidated financial statements following a major asset restructuring[4] Assets and Cautionary Notes - Total assets at the end of the reporting period were CNY 4,906.49 million, a decrease of 6.72% from the beginning of the period[3] - Investors are advised to be cautious as the reported financial data for the first three quarters of 2018 is preliminary and unaudited[7]